F

Florida Pharmaceutical Research and Associates | Miami, FL

Research site

(Unclaimed)

Location

7325 Southwest 63rd Avenue Suite 203B, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

Molnupiravir

Amlitelimab

Albuterol Sulfate

Deuruxolitinib

Fluticasone Propionate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 7 total trials

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (MOVe-NOW)

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symp...

Enrolling

Coronavirus Disease (COVID-19)

Drug: Placebo

Drug: Molnupiravir

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germ...

Enrolling

Pneumococcal Disease

Biological: PG4

Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

The primary objective of the study is to assess the efficacy of high dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic m...

Active, not recruiting

Asthma

Drug: TEV-56248

Drug: Albuterol sulfate

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (ATLANTIS)

This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD).The purpose of thi...

Active, not recruiting

Dermatitis Atopic

Drug: Amlitelimab

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair l...

Enrolling

Alopecia Areata

Drug: Placebo

Drug: Deuruxolitinib